Kelly Evans is co-anchor of CNBC's "Closing Bell" (M-F, 3PM-5PM ET). She joined the network in February 2012 as an on-air correspondent, reporting across CNBC's Business Day programming.
Prior to CNBC, Evans was a reporter and columnist for The Wall Street Journal, penning the influential "Ahead of the Tape" column and writing for "Heard on the Street." She also hosted the daily "News Hub" program on WSJ.com and was a frequent guest on television and radio networks, including CNBC. Evans joined the Journal in 2007 as a reporter covering real estate and economics.
Evans graduated magna cum laude with a bachelor's degree from Washington & Lee University in Lexington, Va., where she was a George Washington Honor Scholar, a four-time scholar-athlete, and inducted into the national leadership society, Omicron Delta Kappa.
Billionaire investor Warren Buffett had a very short window on Thursday where a big bet paid off, aside from an already hefty pile of dividends.
Art Cashin, of UBS, discusses what to watch in the last half hour of trading.
Discussing the current state of the markets with Jonathan Corpina, Meridian Equity Partners; Kevin Giddis, Raymond James; and CNBC's Rick Santelli.
Kevin Landis, Firsthand Capital Management, and Alan Gould, Brean Capital, share their reactions to Netflix Q4 earnings.
Mark Lehmann, JMP Securities, and Kevin Caron, Washington Crossing Advisors, weigh in on current market environment.
Academy Award winner Matthew McConaughey discusses his role in new movie "Gold," his biggest money mistake and advice for Millennials.
Michael Ward, CSX CEO, discusses Q4 earnings and his outlook for 2017 under a Trump presidency.
Matthew Desch, Iridium Communications CEO, speaks to CNBC's Morgan Brennan about SpaceX's recent launch of Iridium satellites into space, and the "ambitious schedule" to come.
Tech blogger Robert Scoble, Transformation Group, and Gene Munster, Loup Ventures founder, discuss new augmented reality technology and whether Apple will pull through on innovation.
People are waiting for plans to repeal Obamacare, but Terry Haines believes that process will take longer than expected.
The market likes Trump's pro-growth policies but is concerned about his protectionist tendencies, Mohamed El-Erian said.
Financials may have pared back some of their gains, but all signs point to a positive outlook, Dick Kovacevich said.
With Trump's inauguration less than a day away, investors are anxiously waiting to see what new regulations could influence bank outlooks.
Anything can happen between the bells of the trading day. But what happens during the last hour could be what matters most. CNBC's "Closing Bell" guides you through the most important hour of the trading day. The show takes a close-up look at how the markets are moving, what's driving them and how investors are reacting.
Live coverage includes reports from the Chicago Board of Trade, New York Mercantile Exchange, NASDAQ and the NYSE. Analysts, money managers and CEOs explain their strategies, share opinions, and provide an inside perspective on breaking news stories.
In addition, "Closing Bell" provides instant analysis of corporate profit reports, as soon as they break, during the quarterly earning seasons. Features include interviews with entrepreneurs, plus an inside-look at how executives and high-net-worth individuals spend their time and money.
Actor Matthew McConaughey has some advice for those who, to borrow his dad's phrase, haven't "gotten their 'lick' yet."
Professional investors appear simultaneously excited about the 'melt up' and wary about what could be next.
The increasing demand for high-tech skills is putting a greater emphasis on tech boot camps as the new trade schools.
Scott Stringer, NYC Comptroller, and CNBC contributor Bob Lutz, former GM vice chairman, weigh in on allegations against Fiat Chrysler from the EPA over diesel emission software.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.
Katrine Bosley, Editas CEO, speaks to CNBC's Meg Tirrell about gene editing and the future of disease treatment.